Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Xeris Biopharma Holdings Inc shares valued at $120,000 were sold by McCulloch Kevin on Jan 08 ’26. At $8.00 per share, McCulloch Kevin sold 15,000 shares. The insider’s holdings dropped to 1,685,426 shares worth approximately $12.84 million following the completion of this transaction.
Also, KEVIN MCCULLOCH purchased 60,000 shares, netting a total of over 432,600 in proceeds.
Before that, Shannon John Patrick Jr had sold 24,907 shares from its account. In a trade valued at $176,257, the insider traded Xeris Biopharma Holdings Inc shares for $7.08 each. Upon closing the transaction, the insider’s holdings decreased to 24,907 shares, worth approximately $20.61 million.
As published in their initiating research note from Barclays on December 09, 2025, Xeris Biopharma Holdings Inc [XERS] has been an Overweight and the price target has been revised to $9. As of November 11, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for XERS. Earlier on March 28, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for XERS stock.
Analyzing XERS Stock Performance
On last trading session, Xeris Biopharma Holdings Inc [NASDAQ: XERS] rose 0.13% to $7.62. The stock’s lowest price that day was $7.465, but it reached a high of $7.7082 in the same session. During the last five days, there has been a drop of approximately -1.17%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 138.12%.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.55 million shares to 16.52 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 15.97 million shares. A jump of 3.32% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.51 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.51.
Which companies own the most shares of Xeris Biopharma Holdings Inc (XERS)?
In terms of Xeris Biopharma Holdings Inc share price expectations, FactSet research, analysts set an average price target of 13.5 in the next 12 months, up nearly 77.4% from the previous closing price of $7.61. Analysts anticipate Xeris Biopharma Holdings Inc stock to reach 18 by 2026, with the lowest price target being 9. In spite of this, 3 analysts ranked Xeris Biopharma Holdings Inc stock as Buy at the end of 2026. On August 28, 2023, Craig Hallum assigned a price target of “a Buy” to the stock and initiated coverage with a $4.50.
